JUPITER, Fla., May 10 /PRNewswire-FirstCall/ -- Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic"), a leading-edge early-stage biotechnology company, announced today that its President and Chief Executive Officer, Mark Emalfarb, is scheduled to present at the Rodman & Renshaw 6th Annual Global Healthcare Conference in London, England on Monday, May 17, 2010 at 11:05 a.m. local time (6:05 a.m. EDT). Mr. Emalfarb will discuss how Dyadic is applying its proprietary C1 platform technology for producing human antibodies and other high-value therapeutic proteins in addition to its other industrial uses for growth markets such as cellulosic ethanol, pulp & paper, animal feed, and starch and alcohol.
The PowerPoint presentation will be accessible after the conference on Dyadic's website at www.dyadic.com.
Dyadic is a leading-edge early-stage biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes. Dyadic also utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins a
|SOURCE Dyadic International, Inc.|
Copyright©2010 PR Newswire.
All rights reserved